Key Points
- SVP Lauren Riker sold 1,416 shares on Jan. 5 at an average price of $24.24 for $34,323.84, reducing her stake by 2.34% to 59,064 shares (transaction disclosed in an SEC filing).
- Pacira beat Q3 EPS estimates ($0.70 vs. $0.65) while revenue of $179.5M slightly missed consensus; the stock trades near its 50/200-day averages (~$24.30) with a market cap of about $1.09 billion and a PE of 56.25.
- Analyst sentiment is mixed — the consensus rating is "Hold" with a $28.20 target, and institutional investors own roughly 99.73% of the shares.
Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) SVP Lauren Riker sold 1,416 shares of the firm's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $24.24, for a total transaction of $34,323.84. Following the completion of the transaction, the senior vice president directly owned 59,064 shares of the company's stock, valued at approximately $1,431,711.36. This trade represents a 2.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Pacira BioSciences Trading Up 0.8%
Shares of NASDAQ:PCRX opened at $25.31 on Wednesday. The company's 50-day moving average price is $24.30 and its two-hundred day moving average price is $24.22. Pacira BioSciences, Inc. has a one year low of $18.18 and a one year high of $27.64. The company has a debt-to-equity ratio of 0.52, a current ratio of 5.26 and a quick ratio of 3.78. The stock has a market capitalization of $1.09 billion, a PE ratio of 56.25 and a beta of 0.22.
Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Pacira BioSciences had a return on equity of 12.82% and a net margin of 2.99%.The business had revenue of $179.52 million for the quarter, compared to the consensus estimate of $182.86 million. During the same quarter in the previous year, the business earned $0.79 earnings per share. Pacira BioSciences's quarterly revenue was up 6.5% on a year-over-year basis. On average, equities analysts forecast that Pacira BioSciences, Inc. will post 2.41 EPS for the current fiscal year.
Hedge Funds Weigh In On Pacira BioSciences
Several institutional investors and hedge funds have recently modified their holdings of the stock. Hantz Financial Services Inc. raised its position in shares of Pacira BioSciences by 175.4% in the third quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company's stock valued at $29,000 after purchasing an additional 721 shares during the period. Tidemark LLC acquired a new position in Pacira BioSciences in the 3rd quarter valued at about $56,000. Strs Ohio acquired a new position in Pacira BioSciences in the 1st quarter valued at about $75,000. iSAM Funds UK Ltd bought a new position in Pacira BioSciences in the 3rd quarter valued at about $80,000. Finally, PNC Financial Services Group Inc. lifted its position in Pacira BioSciences by 17.8% during the second quarter. PNC Financial Services Group Inc. now owns 3,511 shares of the company's stock worth $84,000 after acquiring an additional 531 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
PCRX has been the subject of several analyst reports. Barclays began coverage on shares of Pacira BioSciences in a research note on Tuesday, December 9th. They issued an "equal weight" rating and a $27.00 target price for the company. Weiss Ratings reiterated a "sell (d+)" rating on shares of Pacira BioSciences in a research note on Monday, December 29th. Truist Financial lowered their price objective on shares of Pacira BioSciences from $30.00 to $28.00 and set a "buy" rating on the stock in a research note on Friday, November 7th. HC Wainwright reaffirmed a "buy" rating and issued a $38.00 target price on shares of Pacira BioSciences in a report on Monday, November 17th. Finally, Wall Street Zen upgraded Pacira BioSciences from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 8th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Pacira BioSciences presently has an average rating of "Hold" and a consensus target price of $28.20.
Check Out Our Latest Research Report on Pacira BioSciences
Pacira BioSciences Company Profile
(
Get Free Report)
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
